Wave of AI and data science tools set to transform clinical trials
The clinical trial sector is experiencing a rapid influx of artificial intelligence (AI) and data science tools, as companies seek…
All articles by Abigail Beaney
Abigail Beaney
Abigail Beaney is the editor of Clinical Trials Arena. Abigail has expertise in clinical trial regulation, trial design, outsourcing, and cell and gene therapies. Abigail also has covered news and has a wealth of knowledge across several therapy areas including neurodegenerative, infectious and metabolic diseases. Abigail holds a first-class BA (Hons) degree in Journalism from the University of Central Lancashire in the United Kingdom. She has also obtained the National Qualification in Journalism through the UK's media industry body, the National Council for the Training of Journalists. Contact Abigail
-
-
Pfizer hoping for earlier Elrexfio use in RRMM after Phase III trial
Pfizer is hoping for earlier use of Elrexfio (elranatamab) in relapsed or refractory multiple myeloma (RRMM) after the drug showed…
-
Boehringer’s weight loss jab as good as Wegovy but not Zepbound
Boehringer Ingelheim’s (BI’s) weight loss jab has shown similar efficacy to Wegovy (semaglutide) but a strength inferior to Zebound (tirzepatide).…
-
FDA launches pilot for real-time clinical trials
The US Food and Drug Administration (FDA) is launching a pilot to implement real-time clinical trials (RTCT). While announcing the…
-
UK trial reforms come into effect, but scepticism remains
The UK clinical trial regulation reforms should help make the region more attractive for clinical development, but proper adoption will…
-
Compass Therapeutics’s stock crashes after OS miss in BTC trial
Compass Therapeutics’ stock has dropped by more than 60% after a Phase II/III trial of its biliary tract cancer (BTC)…
-
Intellia’s in vivo gene therapy victorious in Phase III HAE trial
Intellia Therapeutics is set to seek US approval of its in vivo CRISPR gene therapy in hereditary angioedema (HAE) after…
-
Africa-Europe partnership delivers first clinical trial for malaria in early pregnancy
A partnership between Europe and Africa has seen the initiation of a clinical trial of an anti-malaria drug in early…
-
J&J’s Imaavy shows two-year benefit in gMG
Johnson & Johnson’s (J&J’s) Imaavy (nipocalimab-aahu) has shown continued benefit for two years in patients with generalised myasthenia gravis (gMG)…
-
Safety concerns continue to plague Roche’s BTK inhibitor in RMS
Roche’s BTK inhibitor, fenebrutinib, cuts relapse rates in patients with relapsing multiple sclerosis (RMS), but safety concerns continue to cloud…